Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cardiopulmonary Resuscitation IV: Pharmacological Management01:25

Cardiopulmonary Resuscitation IV: Pharmacological Management

1.2K
Pharmacologic intervention is crucial in treating cardiac arrest patients during ACLS or Advanced Cardiovascular Life Support. The ACLS algorithms guide the administration of specific drugs based on the patient's cardiac arrest rhythm, which includes pulseless ventricular tachycardia (VT), ventricular fibrillation (VF), asystole, and pulseless electrical activity (PEA).EpinephrineIndication: Epinephrine is the first-line drug for all cardiac arrest rhythms.Mechanism of Action: Epinephrine...
1.2K
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

627
Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
627
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

725
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
725
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

584
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
584

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Transfection of IFNalpha in human glioblastoma cells and tumorigenicity in association with induction of PKR and OAS gene expression.

Journal of neurosurgery·1996
Same author

In vitro transcriptional analysis of TyrR-mediated activation of the mtr and tyrP+3 promoters of Escherichia coli.

Journal of bacteriology·1996
Same author

Case report: ranitidine-induced bradycardia in a patient with dextrocardia.

The American journal of the medical sciences·1996
Same author

Antioxidant-sensitive regulation of inflammatory-response genes in Kaposi's sarcoma cells.

Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association·1996
Same author

Cytokine expression in the presence or absence of late airway responses after antigen challenge of sensitized rats.

American journal of respiratory cell and molecular biology·1996
Same author

Injuries of the abdominal aorta and inferior vena cava in association with thoracolumbar fractures: a lethal combination.

The Journal of trauma·1996

Related Experiment Video

Updated: Mar 17, 2026

In vitro Assessment of Myocardial Protection following Hypothermia-Preconditioning in a Human Cardiac Myocytes Model
08:22

In vitro Assessment of Myocardial Protection following Hypothermia-Preconditioning in a Human Cardiac Myocytes Model

Published on: October 27, 2020

3.5K

Cardioprotection by Thymosin Beta 4.

G T Pipes1, J Yang1

  • 1Cardiovascular Drug Discovery, Discovery Biology Research & Development, Bristol-Myers Squibb, Pennington, NJ, United States.

Vitamins and Hormones
|July 25, 2016
PubMed
Summary
This summary is machine-generated.

Thymosin beta 4 (Tβ4) treatment reduced heart damage and improved cardiac function in preclinical studies. Its antifibrotic and proangiogenic properties promote healing and blood vessel growth after ischemic injury.

Keywords:
AngiogenesisCardioprotectionMyocardial infarctionThymosin

More Related Videos

Protection of H9c2 Myocardial Cells from Oxidative Stress by Crocetin via PINK1/Parkin Pathway-Mediated Mitophagy
07:40

Protection of H9c2 Myocardial Cells from Oxidative Stress by Crocetin via PINK1/Parkin Pathway-Mediated Mitophagy

Published on: May 26, 2023

1.7K
Pluripotent Stem Cell Derived Cardiac Cells for Myocardial Repair
06:37

Pluripotent Stem Cell Derived Cardiac Cells for Myocardial Repair

Published on: February 3, 2017

8.9K

Related Experiment Videos

Last Updated: Mar 17, 2026

In vitro Assessment of Myocardial Protection following Hypothermia-Preconditioning in a Human Cardiac Myocytes Model
08:22

In vitro Assessment of Myocardial Protection following Hypothermia-Preconditioning in a Human Cardiac Myocytes Model

Published on: October 27, 2020

3.5K
Protection of H9c2 Myocardial Cells from Oxidative Stress by Crocetin via PINK1/Parkin Pathway-Mediated Mitophagy
07:40

Protection of H9c2 Myocardial Cells from Oxidative Stress by Crocetin via PINK1/Parkin Pathway-Mediated Mitophagy

Published on: May 26, 2023

1.7K
Pluripotent Stem Cell Derived Cardiac Cells for Myocardial Repair
06:37

Pluripotent Stem Cell Derived Cardiac Cells for Myocardial Repair

Published on: February 3, 2017

8.9K

Area of Science:

  • Cardiovascular Research
  • Regenerative Medicine
  • Molecular Biology

Background:

  • Cardiac ischemic injury leads to infarcts, fibrosis, and impaired cardiac function.
  • Thymosin beta 4 (Tβ4) is a bioactive peptide with known regenerative properties.
  • Previous studies suggest Tβ4 may have therapeutic potential in cardiac conditions.

Purpose of the Study:

  • To evaluate the efficacy of thymosin beta 4 (Tβ4) in preclinical models of cardiac ischemic injury.
  • To investigate the mechanisms underlying Tβ4's cardioprotective effects, including its antifibrotic and proangiogenic activities.

Main Methods:

  • Administration of Tβ4 (injected or transgenic) in animal models of cardiac ischemia.
  • Assessment of infarct volume, cardiac function, blood vessel growth, and fibrotic markers.
  • Analysis of Tβ4's interactions with cellular signaling pathways, including the SRF-MRTF-G-actin pathway.

Main Results:

  • Tβ4 treatment significantly reduced infarct volume and preserved cardiac function.
  • Tβ4 demonstrated potent antifibrotic effects in vitro and in vivo.
  • Tβ4 promoted significant blood vessel growth (angiogenesis) in models of cardiac injury.
  • Tβ4 influences cellular motility and movement via the SRF-MRTF-G-actin pathway.

Conclusions:

  • Thymosin beta 4 (Tβ4) exhibits significant cardioprotective effects in preclinical models of cardiac ischemic injury.
  • Tβ4's benefits are attributed to reduced infarct size, antifibrotic activity, and proangiogenic effects.
  • Further preclinical studies on pharmacokinetics, pharmacodynamics, and reliable biomarkers are needed for clinical development.